Sexual dysfunction in patients with cancer: Results from the CLARIFY project.

Aylen Vanessa Ospina Serrano Instituto de Investigacion Sanitaria Puerta de Hierro - Segovia de Arana. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain info_outline Aylen Vanessa Ospina Serrano, Constanza Maximiano, Blanca Cantos Sanchez de Ibarguren, Maria Torrente, Miriam Mendez, Juan Cristobal Sanchez, Virginia Calvo, Ana Collazo Lorduy, Mariola Blanco, Beatriz Nuñez García, Ivan Triana, Consuelo Parejo, Paula Martinez, Narjust Florez, Mariano Provencio-Pulla

Authors Aylen Vanessa Ospina Serrano Instituto de Investigacion Sanitaria Puerta de Hierro - Segovia de Arana. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain info_outline Aylen Vanessa Ospina Serrano, Constanza Maximiano, Blanca Cantos Sanchez de Ibarguren, Maria Torrente, Miriam Mendez, Juan Cristobal Sanchez, Virginia Calvo, Ana Collazo Lorduy, Mariola Blanco, Beatriz Nuñez García, Ivan Triana, Consuelo Parejo, Paula Martinez, Narjust Florez, Mariano Provencio-Pulla Organizations Instituto de Investigacion Sanitaria Puerta de Hierro - Segovia de Arana. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda., Spain, Instituto Investigacion Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, NY, Spain, Fundación Santa Fe de Bogota, Bogotá, Colombia, Instituto Investigación Sanitaria Puerta de Hierro - Segovia de Aran. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Hospital Universitario Puerta de Hierro, Madrid, Spain Abstract Disclosures Research Funding Other Government Agency European Commision, H2020 programme Background: Survivors patients with cancer may suffer long-term consequences related to antineoplastic treatments and tumor itself, leading to deterioration of quality of life and resulting in disturbances including sexual dysfunction (SD). We aimed to identify and characterize SD in a cohort of Spanish patients. Methods: Analytical observational study in patients included in the CLARIFY H2020 project at the Hospital Universitario Puerta de Hierro. From October 2020 to May 2022, clinical and demographic variables were collected as well as measures of sexual function using a validated Spanish-language, gender-targeted separately questionnaire. A descriptive domain on frequency of sexual activity during the last four weeks (DFSA) and multiple domains assessing phases of sexual response (DESR), according to DSM IV and DSM V parameters including desire, arousal, lubrication, orgasm, satisfaction with sexual performance, global sexual satisfaction, anticipatory anxiety and sexual initiative were evaluated. Descriptive, trend associations and logistic regression analyses were performed. Results: 383 patients were included, cancer type distribution was breast cancer 68.14% (261), lung cancer 26.37% (101) and lymphomas 5.50% (21). The average age was 56.5 years (range 33-88). 19.58% (75) of patients were men and 80.42% (308) woman. 69% of men and 31% of women reported they were sexually active. The absolute frequency of Global sexual dissatisfaction (GSD) was 76% in women and 24% in men, according to neoplasia; GSD was 36% in patients with early breast cancer, 14% in men with lymphoma, and 9% in men with lung cancer. Women with metastatic breast cancer presented the highest tendency to have severe disorders of DESR. In multinomial logistic regression, significant associations were found in women with metastatic breast cancer and severe disorders of: arousal (p 0.000), lubrication (p 0.002) orgasm (p 0.000), as well as dissatisfaction with sexual performance (p 0.000) and global sexual dissatisfaction (p 0.000). On the other hand, in women with lung cancer, severe arousal disorder (p 0.016) and global sexual dissatisfaction (p 0.044) were observed. Table. Conclusions: In our study, cancer survivors have high prevalence of SD related with oncological treatment and clinical characteristics of malignancy, being women the most affected population. Efforts should be made to support SD during follow-up to improve the quality of life of this growing oncologic population. Breast cancer (BC). Sexual performance dissatisfaction Metastatic breast cancer p 0.000 OR 5.14 IC 95% (2.19-12.06) Early breast cancer p 0.000 OR 2.61 IC 95% (1.37-4.98) Long-term survivors BC 1 ref. G lobal sexual dissatisfaction Metastatic breast cancer p 0.000 OR 4.4 IC 95% (1.94-10.22) Long-term survivors BC 1 ref. LUNG CANCER Global sexual dissatisfaction Women with lung cancer p 0.044 OR 3.12 IC 95% (1.02-9.51) Men with lung cancer 1 ref.